Product Images Temodar

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Temodar NDC 54868-4142 by Physicians Total Care, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PRINCIPAL DISPLAY PANEL - 20 mg Capsule - 4142

PRINCIPAL DISPLAY PANEL - 20 mg Capsule - 4142

PRINCIPAL DISPLAY PANEL - 5 mg Capsule - 5348

PRINCIPAL DISPLAY PANEL - 5 mg Capsule - 5348

PRINCIPAL DISPLAY PANEL - 100 mg Capsule - 5350

PRINCIPAL DISPLAY PANEL - 100 mg Capsule - 5350

PRINCIPAL DISPLAY PANEL - 250 mg Capsule - 5354

PRINCIPAL DISPLAY PANEL - 250 mg Capsule - 5354

Not available. The text seems to be a collection of random characters without any apparent meaning or coherence.*

PRINCIPAL DISPLAY PANEL - 180 mg Capsule - 5980

PRINCIPAL DISPLAY PANEL - 180 mg Capsule - 5980

This text contains information about a medication called "Tehodar" which is a 186KG capsule distributed by Physicians Total Care. The medication has an NDC number of 54868-5986-0 and comes in a 14 capsule package. The lot number is 6000 and the expiration date is 61/60. There is also a code of "WG W SoERIG coomTion" and a number of "59208140000".*

Table 4: Dosing Modification Table - temodar 01

Table 4: Dosing Modification Table - temodar 01

This seems to be a medical document with instructions on dosage and measurement for a therapy cycle. The starting dose is either 150 mgim?/d x 54 or 200 mg/m?/d x 5. Measurements need to be taken on Day 22 and Day 29 for ANG, platelets, and ANC. The decision on whether to postpone therapy or maintain the dose depends on the count of ANC and platelets on Day 22 and Day 29. If ANC is less than 1000/uL or platelets are less than 50,000/uL, then therapy should be postponed. If ANC is greater than 15004L and platelets are greater than 100,000/L, then it is okay to continue with the therapy. Otherwise, the dosage should be adjusted.*

Chemical Structure - temodar 02

Chemical Structure - temodar 02

FIGURE 1: Kaplan-Meier Curves for Overall Survival (ITT Population) - temodar 03

FIGURE 1: Kaplan-Meier Curves for Overall Survival (ITT Population) - temodar 03

The text seems to be a statistical analysis of a medical study regarding Overall Survival in an ITT (Intent-to-Treat) Population. The HR (Hazard Ratio) is reported as 0.63 with a 95% CI (Confidence Interval) of 0.52-0.75, which suggests a statistically significant benefit in the group being studied. The analysis seems to have been conducted over a period of 24 months and the p-value is reported as less than 0.0001.*

Table - temodar 04

Table - temodar 04

This appears to be a medical document with dosing instructions for a medication. The starting dose is either 150 mg, taken once a day for five days, or 200 mg taken once a day for five days. On day 22, ANC and platelets should be measured, and on day 20 of the next cycle, they should be measured again. If ANC is less than 1,000/uL or platelets are less than 50,000/uL, the dose should be postponed or reduced by 50% for the subsequent cycle. If ANC is between 1,000-1,499/uL or platelets are between 50,000-99,999/uL, the dose may be continued with caution. If ANC is 1,500/uL or greater and platelets are 100,000 or greater, the dose may be continued as normal.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.